Prognostic value of chromosomal aberrations in relapsed multiple myeloma patients treated by thalidomide
| Authors | |
|---|---|
| Year of publication | 2009 |
| Type | Conference abstract |
| MU Faculty or unit | |
| Citation | |
| Description | We have focused on following chromosomal aberrations: del(13)(q14), del(17)(q13), t(4;14), gain/amplification (1q21) and non-hyperdiploidy. All of these aberrations are known as negative prognostic factor in multiple myeloma patients. The aim of this study is to determine the prognostic value of these selected aberrations in relapsed patients treated by novel agent thalidomide. For identification of plasma cells in bone marrow samples we have used the AMCA antibody based imunofluorescent labeling protocol or MACS technique. For detection of chromosomal abnormalities the I-FISH technique has been used. Cytogenetic findings:del(13)(q14) was found in 42 % (16/38), del(17)(q13) in 8 % (3/37), translocation t(4;14) in 20 % (7/35), amplification of 1q21 in 47,2 % (17/36) and non-hyperdiploidy in 60 % (18/30) patients. Our results suggest that no one of monitored aberrations seems to have any impact on efficiency of used treatment. It is possible that thalidomide overcome the negative impact of cytogenetic aberrations except gain/amplification 1q21. We will continue in this research to reach larger data set to confirm or disconfirm our results. |
| Related projects: |